Bio-Rad Laboratories (BIO) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
Bio-Rad Laboratories (BIO) Net Income towards Common Stockholders Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 51.47% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -7.83% |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | 11.15% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 1,825.47% |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 17.54% |
| 10 | Bio-Rad Laboratories | 10.07 Bn | 8.46 Bn | 345.80 Mn | 32.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.37% |
| Mar 31, 2026 | -112.85% |
| Dec 31, 2025 | -4.54% |
| Sep 30, 2025 | -28.06% |
| Jun 30, 2025 | 32.83% |
| Mar 31, 2025 | 26.39% |
| Dec 31, 2024 | 22.96% |
| Sep 30, 2024 | -45.01% |
| Jun 30, 2024 | -63.48% |
| Mar 31, 2024 | -26.77% |
| Dec 31, 2023 | -25.54% |
| Sep 30, 2023 | -56.77% |
| Jun 30, 2023 | -47.40% |
| Mar 31, 2023 | -53.50% |
| Dec 31, 2022 | 14.36% |
| Sep 30, 2022 | 14.32% |
| Jun 30, 2022 | -52.48% |
| Mar 31, 2022 | -80.61% |
| Dec 31, 2021 | -23.63% |
| Sep 30, 2021 | 144.32% |